Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $111.5MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bienaime Jean Jacques | Director | Aug 14 '26 | Buy | $246.33 | 2,000 | $492,654 | 2,900 | Aug 18 09:02 PM |
| Smith Scott Thomas | EVP & Chief Financial Officer | Jun 02 '26 | Buy | $219.00 | 100 | $21,900 | 4,367 | Jun 02 04:25 PM |
| Bienaime Jean Jacques | Director | May 29 '26 | Buy | $223.12 | 500 | $111,562 | 900 | Jun 01 04:11 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.